GlassScriptPhysician profile
Leilani Lim
NPI 1316468226
$19,344.63
in general payments reported to CMS, 2019-2025
50 companies · $4,847 in 2025
The $4,847 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,865 · 2022: $3,143 · 2023: $3,797 · 2024: $4,692 · 2025: $4,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,319.75 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,844.92 | 2021-2025 | Fintepla, Briviact, Nayzilam |
| Abbvie INC. | $2,707.90 | 2021-2025 | |
| Sk Life Science, INC. | $1,423.68 | 2021-2025 | Xcopri |
| Pfizer INC. | $952.45 | 2023-2025 | |
| Eisai INC. | $839.11 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $761.30 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $692.81 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $689.41 | 2021-2025 | Daybue, Nuplazid |
| Catalyst Pharmaceuticals, INC. | $688.38 | 2023-2025 | Fycompa |
| Livanova USA, INC. | $648.63 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Lilly USA, LLC | $628.54 | 2021-2025 | Amyvid, Emgality, Kisunla |
| Neurelis, INC. | $602.68 | 2021-2025 | Valtoco |
| Biogen, INC. | $547.90 | 2021-2025 | Leqembi, Vumerity, Tysabri |
| Amgen INC. | $415.41 | 2021-2025 | Uplizna |
| Biohaven Pharmaceuticals, INC. | $408.52 | 2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leilani Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.